Role of Type 1 Interferons therapy on Adverse Clinical Outcomes on COVID-19 in Hospitalized Multiple Sclerosis Patients

por Maghbooli, Zhila, Sahraian, Mohammad Ali., Fattahi, Mohammad Reza, Varzandi, Tarlan, Hamtaeigashi, Sara, Mohammad-Nabi, Sara, Aghababaei, Yasaman
Publicado 2023

Association between disease-modifying therapies and adverse clinical outcomes in multiple sclerosis patients with COVID-19 infection

por Maghbooli, Zhila, Hosseinpour, Hesham, Fattahi, Mohammad Reza, Varzandi, Tarlan, Hamtaeigashi, Sara, Mohammad-nabi, Sara, Aghababaei, Yasaman, Sahraian, Mohammad Ali
Publicado 2022